Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. (AKBA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
akba · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Akebia Therapeutics, Inc. (AKBA) measures how much investors pay for each dollar of the company's trailing earnings. AKBA's current PE ratio of N/A is calculated by dividing its stock price of $0.92 by its TTM earnings per share of -$0.08.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Akebia Therapeutics, Inc.You AKBA | $247M | N/A | — | -$0.08 |
 Compass Therapeutics, Inc. CMPX | $279M | N/A | — | -$0.42 |
 Corvus Pharmaceuticals, Inc. CRVS | $944M | N/A | — | -$0.19 |
 4D Molecular Therapeutics, Inc. FDMT | $448M | N/A | — | -$2.42 |
 Gossamer Bio, Inc. GOSS | $39M | N/A | — | -$0.75 |
 KalVista Pharmaceuticals, Inc. KALV | $1.4B | N/A | — | -$3.23 |
 Olema Pharmaceuticals, Inc. OLMA | $871M | N/A | — | -$1.87 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.02 | — | |
2024-12-31 FY2024 | — | $-0.33 | — | |
2023-12-31 FY2023 | — | $-0.28 | — | |
2022-12-31 FY2022 | — | $-0.52 | — | |
2021-12-31 FY2021 | — | $-1.70 | — | |
2020-12-31 FY2020 | — | $-2.78 | — | |
2019-12-31 FY2019 | — | $-2.36 | — | |
2018-12-31 FY2018 | — | $-1.47 | — | |
2017-12-31 FY2017 | — | $-1.77 | — | |
2016-12-31 FY2016 | — | $-3.60 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Akebia Therapeutics, Inc. (AKBA) measures how much investors pay for each dollar of the company's trailing earnings. AKBA's current PE ratio of N/A is calculated by dividing its stock price of $0.92 by its TTM earnings per share of -$0.08.
Frequently asked questions
AKBA pe ratio · 6 questionsAKBA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.92 and TTM EPS of -$0.08. Data sourced from Financial Modeling Prep via AKBA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Akebia Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08